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Research for novel Brucella vaccines has focused upon the development of live vaccine strains, which have
proven more efficacious than killed or subunit vaccines. In an effort to develop improved vaccines, signature-
tagged mutant banks were screened to identify mutants attenuated for survival. Mutants selected from these
screens exhibited various degrees of attenuation characterized by the rate of clearance, ranging from a failure
to grow in macrophages after 24 h of infection to a failure to persist in the mouse model beyond 8 weeks. Ideal
vaccine candidates should be safe to the host, while evoking protective immunity. In the present work, we
constructed unmarked deletion mutants of three gene candidates, manBA, virB2, and asp24, in both Brucella
abortus and Brucella melitensis. The asp24 mutants, which persist for extended periods in vivo, are superior
to current vaccine strains and to other deletion strains tested in the mouse model against homologous
challenge infection after 12, 16, and 20 weeks postvaccination. The asp24 mutants also display superior
protection compared to manBA and virB2 mutants against heterologous challenge in mice. From this study,
a direct association between protection against infection and cytokine response was not apparent between all
vaccine groups and, therefore, correlates of protective immunity will need to be considered further. A distinct
correlation between persistence of the vaccine strain and protection against infection was corroborated.
Brucella species are small, facultative, gram-negative, intra-
cellular coccobacilli that are classified phylogenetically within
the -2 subdivision of Proteobacteria. Several species of Bru-
cella are the etiologic agents of brucellosis, a disease affecting
numerous animal species that is also a zoonotic disease for
humans (4, 15, 17, 29, 39). Animal exposure most commonly
occurs through inhalation, in utero exposure from infected
mothers to calves, ingestion of infected fetal tissues, or in some
cases may be sexually transmitted (29). Acute infections in
animal hosts are observed after Brucella organisms invade the
chorionic trophoblast cells of the placenta, resulting in abor-
tion of the fetus. Persistence is then classified by the organism’s
ability to reside in reproductive tissues and the mammary gland
and lymph nodes, chronically shedding into the milk (18).
Animal brucellosis can be a serious cause of economic loss due
to abortion and infertility and also represents a public health
threat (22, 40).
In the United States, Brucella abortus infection in cattle has
been controlled by the combined use of vaccination, testing for
exposure, and slaughter of seropositive animals, but the dis-
ease has not been successfully eradicated in wildlife species.
Commonly, S19 and RB51 have been used for vaccination, but
these vaccines are not ideal for all wildlife species at risk. S19
may cause abortion when administered to pregnant animals,
and RB51 fails to protect most wildlife species from challenge
infection (12, 14). As a result, improved vaccines need to be
designed that will combine safety and efficacy to all species at
risk, including domestic herds and wildlife. The scope of Bru-
cella research has also expanded to include the demand for
better protection and reaction of the United States against
potential bioterrorist threats. Superior vaccine strains are
therefore in demand for improved protection of agricultural
and wildlife reservoirs as well as direct intervention in human
infection.
Numerous attenuated mutants have been identified in Bru-
cella species via signature-tagged mini-Tn5 mutagenesis to
identify Brucella genes encoding factors or products vital for
survival and virulence within the host (2, 17, 25, 32). Mutants
defective for genes required early in infection are rapidly
cleared from both the mouse model and from macrophages in
culture. Mutants defective for genes required later in infection
are retained longer in the mouse model and, depending on the
defect, may or may not show any difference in the macrophage
assay (24). Since mice infected via intraperitoneal injection
with wild-type Brucella abortus retain bacteria within the
spleen for up to 24 weeks postinfection, mutant persistence in
the spleen can therefore be compared to wild-type persistence
in the spleen to determine the degree of attenuation of the
mutant (25). Mutants may be classified according to their rate
of clearance from the mouse.
In order to evaluate protection as a function of vaccine
persistence, mutants exhibiting different rates of clearance
were selected for further study. Rough mutants were selected
due to overall interest in their use, such as the approved rough
vaccine strain RB51, due to a lack of interference with diag-
nostic tests (34, 43, 45, 46, 49). Reliance on O-antigen for
serological diagnosis of brucellosis is based on potent antibody
responses directed against this cell surface antigen, and inter-
est in the use of rough organisms as vaccines stems from the
ease of detection of anti-O-antigen antibodies (34, 46). The
rapid clearance of rough organisms, however, is often consid-
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ered a weakness of rough vaccine strains, preventing a long-
term protective immune response (34). Furthermore, the im-
munity induced by RB51 appears to vary from host to host and
is ineffective in several wildlife species (12, 14).
Because of the controversy surrounding the use of rough
vaccines, we chose to evaluate another highly attenuated but
smooth organism, a virB mutant. The virB type IV secretion
system forms a complex serving to secrete or export macro-
molecules (5, 7). Mutations in this operon attenuate Brucella
survival in macrophages and in the mouse model, suggesting
that a completely functional VirB system is necessary for the
establishment and maintenance of infection (5–8, 13, 30). It is
a logical step to construct a knockout of this gene, since it is
part of a macrophage/host cell-specific virulence mechanism
identified in Brucella species.
Mutants that are not rapidly cleared in the mouse model
have been shown to exhibit superior protective immunity; thus,
it was desirable to correlate vaccine efficacy with survival of the
vaccine strain (24). Based on preliminary evidence demonstrat-
ing persistence in macrophages and delayed attenuation in the
mouse model, the asp24 gene was selected as a deletion can-
didate for this study (GenBank accession number AE009508).
The gene encoding Asp24 had never been identified in mutant
screens, consistent with extremely late or reduced attenuation.
MATERIALS AND METHODS
Bacteria and bacterial cultures. Escherichia coli cultures were routinely grown
on Luria-Bertani (Difco Laboratories) plates overnight at 37°C with or without
supplemental kanamycin (100 mg/liter), carbenicillin (100 mg/liter), or chloram-
phenicol (50 mg/liter). All wild-type, vaccine, and unmarked deletion strains
were routinely grown on tryptic soy agar (TSA; Difco Laboratories) at 37°C in an
atmosphere containing 5% (vol/vol) CO2. Virulent B. abortus strain S2308 was
obtained from Billy Deyoe at the National Animal Disease Center in Ames,
Iowa. Brucella melitensis bv. 1 (16M) was obtained from ATCC and reisolated by
this lab from an aborted goat fetus. These strains were used as virulent challenge
organisms and to generate vaccine candidates via deletion mutagenesis. Strain 19
was obtained from the National Veterinary Services Laboratory in Ames, Iowa.
Rev 1 INRA was obtained from Menachem Banai. All bacterial strains were
stored frozen at 80°C in medium supplemented with 50% (vol/vol) glycerol
(Table 1).
Transfection of Brucella was performed via electroporation, using cultures
prepared from the frozen stocks and grown to confluence on TSA at 37°C for 3
days. Bacteria were harvested into phosphate-buffered saline (PBS, pH 7.4;
Gibco) to yield a final suspension containing approximately 4  1011 CFU/ml, as
estimated turbidometrically using a Klett meter.
Inoculation doses used to infect mice were prepared the day of challenge
following growth on solid medium, and the bacterial density was estimated using
TABLE 1. Bacterial strains and plasmids
Strain or plasmid Relevant characteristic(s) Source or reference
B. abortus strains
2308 Wild type B. Deyoe
Strain 19 Vaccine strain NVSL
BAasp24::kan asp24::Km This work
BAasp24 asp24 This work
BAvirB2::kan virB2::Km (polar) This work
BAvirB2 virB2 (nonpolar) This work
BAmanBA manBA This work
B. melitensis strains
16M Wild type Ficht lab
Rev 1 Vaccine strain M. Banai
BMasp24::kan asp24::Km This work
BMasp24 asp24 This work
BMvirB2::kan virB2::Km (polar) This work
BMvirB2 virB2 (nonpolar) This work
BMmanBA::kan manBA::Km This work
BMmanBA manBA This work
E. coli strains
DH5 F 80dlacZM15 (lacZYA-argF)U169 recA1 endA1 hsdR17(rk
 mk
)
phoA supE44  thi-1 gyrA96 relA1
Invitrogen
Top10 F mcrA (mrr-hsdRMS-mcrBC)  80lacZM15 lacX74 recA1
ara139 (ara-leu)7697 galU galK rpsL (Strr) endA1 nupG
Invitrogen
DH10B F mcrA (mrr-hsdRMS-mcrBC)  80lacZM15 lacX74 recA1 endA1
ara139 (ara-leu)7697 galU galK rpsL (Strr) nupG
Invitrogen
Plasmids
pBluescript KS ColE1, bla Stratagene
pKD4 FLP/FRT, Kmr B. Wanner
pEX18Ap sacB bla H. Schweizer
pMMKB TAF101/TAF104 cloned into pEX18Ap This work
pMMK8 TAF101/TAF104 cloned into pBluescript This work
pMMK16 pMMK8 separated by TAF300/TAF301 (kanamycin resistance) This work
pMMK29 TAF356/TAF359 cloned into pBluescript This work
pMMK31 TAF356/TAF359 cloned into pEX18Ap This work
pMMK33 pMMK29 separated by TAF204/205 kanamycin resistance gene This work
pAV2.2 Plasmid to make marked virB2 deletion 13
pAS1.1 Plasmid to make unmarked virB2 deletion 13
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a Klett meter as described above. Inoculum doses were prepared, and serial
dilution was performed retrospectively to accurately determine the number of
organisms inoculated.
Recombinant plasmid construction. In order to construct vectors to eliminate
genes of interest, primers were designed to amplify sequences flanking the genes.
These flanking regions are referred to as the 5 and the 3 fragments and were
joined to one another using specially designed PCR primers (Table 2). Impor-
tantly, the reverse primer of the 5 fragment and the forward primer of the 3
fragment include approximately 5 to 10 nucleotides of sequence complementary
to the opposite fragment and a terminal restriction site. The 5 and 3 fragments
were amplified in separate reactions, gel purified, and used as templates for a
second round of PCR (38). The forward primer of the 5 fragment and the
reverse primer of the 3 fragment were utilized in a second round of PCR to
engineer a product that represented the ligation of the 5 and 3 fragments. The
ends of this joined product were removed by restriction digestion at sites engi-
neered into the primers. The final fragment was gel purified and ligated to
pBluescript II KS() (Stratagene). A kanamycin cassette was inserted between
the 5 and 3 fragments following amplification via PCR from the plasmid pKD4
using primers containing the compatible restriction site located within the over-
lap between the fragments. pKD4 contains nptII from Tn5 flanked by FLP
recombination target sites (11). These constructs are referred to as the marked
plasmids (Table 1).
The construction of the plasmid for creation of unmarked deletion mutants
entails cloning of the original overlapping PCR product (lacking the kanamycin
cassette) into plasmid pEX18Ap, which contains sacB, using the appropriate
restriction enzymes (23). This construct is referred to here as the unmarked
plasmid (Table 1).
Selection of marked deletion mutants. Marked deletion mutants were created
in B. melitensis and B. abortus via allelic exchange following electroporation of
the marked plasmid into either 16M or S2308, respectively. Bacteria were grown
as described above and pelleted via centrifugation at 1,700  g for 15 min at 4°C.
All subsequent steps were performed on ice or at 4°C. The cell pellet was washed
three times with ice-cold sterile water under the same conditions. After the final
wash, the cells were resuspended in 1 ml sterile water. The bacterial cell sus-
pension was used in each electroporation with approximately 1 	g DNA in a
prechilled 1-mm gap cuvette (Bio-Rad, California) and shocked in a BTX elec-
troporation apparatus set at 2.2 to 2.5 kV and 246 
. SOC-B (6% [wt/vol] tryptic
soy broth, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM
glucose) medium was immediately added to the cuvette, transferred to micro-
centrifuge tubes, and incubated overnight at 37°C with agitation (31). Following
incubation, the entire culture was plated onto TSA containing kanamycin. Col-
onies were replica plated onto TSA containing kanamycin and onto plates con-
taining carbenicillin. Marked deletion mutants from allelic exchange should be
kanamycin resistant (Kmr) and carbenicillin sensitive (Carbs). Verification of
mutant genotypes was obtained via PCR and Southern blot analysis to ensure
that the gene of interest was deleted and the kanamycin cassette was retained.
Selection of unmarked deletion mutants. The unmarked plasmid, containing
the sacB gene, ligated 5 and 3 fragments, and bla gene, was used for electro-
poration into marked deletion strains. Electroporation conditions were identical
to those described for the construction of marked mutants. Following electro-
poration, cells were plated onto TSA containing carbenicillin to select for the
first homologous recombination, i.e., a cointegration. Colonies were replica
plated onto sucrose plates (TSA without salt, containing 6% [wt/vol] sucrose,
without antibiotic) and to TSA containing carbenicillin. Colonies that grew on
carbenicillin (Carbr) but not sucrose (Sucs) were cointegrates with a functional
sacB gene. Resolution of cointegration occurs spontaneously and was selected
for by inoculating 5 ml of sucrose broth (TSB, without salt or antibiotics, and
supplemented with 6% [wt/vol] sucrose) and incubating for 24 h with agitation at
37°C, with subsequent plating onto sucrose-containing medium. All knockout
candidates were verified via PCR and Southern blot analysis to demonstrate gene
deletion as well as loss of the kanamycin cassette.
Clearance of mutants from mice. Survival or persistence of mutants was
evaluated following intraperitoneal inoculation of groups of 4- to 6-week-old
female BALB/c mice with 1 105 to 1 106 CFU/ml unmarked deletion mutant
or wild-type organisms. Mice were euthanized via carbon dioxide asphyxiation at
various times postinfection, depending upon the anticipated clearance rate of the
mutant. At each time point, spleens were collected and weighed, homogenized in
1 ml PBS, and serially diluted, and 200-	l aliquots of all dilutions were plated
onto TSA. Recovered bacteria were enumerated to evaluate the persistence of
each individual organism.
Efficacy studies. The mouse model was used to evaluate efficacies of various
unmarked deletion mutants against subsequent virulent infection. Groups of 6 to
10 female 4- to 6-week-old BALB/c mice were vaccinated via intraperitoneal
injection of 1  106 CFU/ml of unmarked deletion mutant or PBS in naı¨ve
controls. Mice were subsequently challenged with 1  104 CFU homologous
wild-type strain at 12, 16, or 20 weeks postvaccination. One week after the
virulent challenge, the mice were euthanized, and spleens were extracted and
weighed, homogenized in 1 ml PBS, serially diluted, and plated onto TSA to
enumerate recovery of the challenge organism.
To evaluate cross-Brucella species protection, groups of five female 4- to
6-week-old BALB/c mice were vaccinated as described above and subsequently
challenged with 1  104 CFU heterologous wild-type strain 16 weeks postvacci-
nation. One week after the virulent challenge, the mice were euthanized and
challenge organisms recovered were enumerated as described above. For both
experiments, vaccine efficacy is presented in units of protection (U), representing
the bacterial (challenge organism) burden in the spleen as a measure of protec-
tive immunity (log10 wild type recovered from unvaccinated mice minus log10
wild type recovered from vaccinates).
Immunological analysis. Correlates of protective immunity were evaluated via
splenocyte cytokine memory responses. Splenocytes were pressed through fine
mesh into complete RPMI (RPMI 1640 [GIBCO Laboratories, Grand Island,
N.Y.] containing L-glutamine, 10% [vol/vol] fetal bovine serum [HyClone Lab-
oratories, Logan, Utah], 1% [vol/vol] sodium pyruvate, 0.1% [vol/vol] -mercap-
toethanol, 1% [vol/vol] penicillin-streptomycin). Cells were pelleted at 1,700  g
for 10 min; 10 ml ACK red blood cell lysis buffer (0.15 M NH4Cl, 10.0 mM
KHCO3, 0.1 mM Na2EDTA) was added to the pellet for 5 min. Splenocytes were
pelleted and washed three times with PBS, enumerated using a hemacytometer,
and then resuspended in complete RPMI to be seeded in triplicate at a density
of 2  105 cells/well in 96-well tissue culture plates (Costar, Massachusetts).
Samples were stimulated for 3 days with either 1  108 CFU heat-killed
homologous Brucella strain or controls, including unstimulated cells for a
baseline level and cells stimulated with 2 	g/ml (wt/vol) concanavalin A
(ConA), a positive control mitogen. Supernatants were collected at day 3 and
frozen at 80°C. Enzyme-linked immunosorbent assays (ELISAs) were per-
formed on supernatants for gamma interferon (IFN-) and interleukin-10
(IL-10) using monoclonal antibody pairs according to the manufacturer’s
protocol (PeproTech, New Jersey).
TABLE 2. Primers used in this study
Primer name Sequence (restriction enzyme engineered) Fragment
TAF101 5-GGAATTCGGCAAAGCGAGTGGGTGATTAG-3(EcoRI) asp24 upstream
TAF102 5-CGGGATCCTGAGCAAGTGCGGGAATAGC-3(BamHI) asp24 upstream
TAF103 5-CGGGATCCTGGGAATGGAGCGGCTTTAG-3(BamHI) asp24 downstream
TAF104 5-GCTCTAGATTTGAACACTTGGCGATAGCG-3(XbaI) asp24 downstream
TAF300 5-CGGGATCCCGCACGTCTTGAGCGATTGTGTAGG-3(BamHI) Kan cassette
TAF301 5-CGGGATCCCGGGACAACAAGCCAGGGATGTAAC-3(BamHI) Kan cassette
TAF356 5-CGGGATCCCTGGAGGAAAACAATCTGGG-3 (BamHI) manBA upstream
TAF357 5-AAGACGGCGCGCCCGAACCTGTATCTGCCTG-3(AscI) manBA upstream
TAF358 5-GTTCGGGCGCGCCGTCTTAACCCAAAACCGCTTCGTA-3(AscI) manBA downstream
TAF359 5-GCTCTAGAGGGTTTTCTGATCGATCTGGTAGC-3(XbaI) manBA downstream
TAF204 5-GGCGCGCCACGTCTTGAGCGATTGTGTAGG-3(AscI) Kan cassette
TAF205 5-GGCGCGCCGGACAACAAGCCAGGGATGTAAC-3(AscI) Kan cassette
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Statistical analysis. Data from survival of mutants as well as in efficacy studies
were expressed as mean CFU  the standard error and were presented graph-
ically as the log10 CFU of Brucella recovered per spleen. Culture-negative
spleens were assigned a value of 4 CFU, which is below the limit of detection of
5 CFU/spleen.
For survival of unmarked strains in mice, analyses of variance (ANOVAs)
were performed to compare individual vaccine groups to the wild-type control
group of the same species. Efficacy studies compared vaccinated and subse-
quently challenged mice to mice receiving PBS as a vaccine control which were
challenged with wild-type organisms. ANOVAs were performed on these sam-
ples as well, comparing the vaccinated groups to nonvaccinated controls. For all
ANOVAs, P values less than 0.05 were considered statistically significant.
RESULTS
Safety of attenuated unmarked deletion mutants in the
mouse model. Infection of mice with unmarked deletion mu-
tants was used to evaluate clearance of the vaccine strain,
modeling field vaccination conditions. Compared to 2308,
the unmarked rough B. abortus manBA deletion mutant
(BAmanBA) was significantly attenuated by 3.4 logs at 1
week postinfection (P  0.0001), 2.4 logs at 2 weeks postin-
fection (P  0.0001), and undetected by 5 weeks postinfection
(P  0.0001). Between 1 and 2 weeks postinfection, the levels
of detectable vaccine strain in the spleens remained unchanged
(Fig. 1A). Unmarked rough B. melitensis deletion mutants of
manBA (BMmanBA) demonstrated a similar clearing trend
as BAmanBA. Compared to wild-type 16M, the mutant was
attenuated 2.5 logs at 1 week (P  0.01), 1.3 logs at 2 weeks
(P  0.001), and undetected by 5 weeks postinfection (P 
0.001) (Fig. 1B). Numbers of bacteria in the spleen remained
unchanged between 1 and 2 weeks postinfection, as was ob-
served in the B. abortus mutant. From these data we consider
the manBA unmarked deletion to be highly attenuated.
Mice infected with unmarked B. abortus virB2 (BAvirB2)
deletion mutants were attenuated 1.6 logs at 2 weeks postin-
fection (P  0.003), though the attenuation compared to 2308
was not as severe as what was demonstrated with the
BAmanBA mutant at the same time point. BAvirB2 was
attenuated 4.7 logs at 6 weeks postinfection (P  0.0001),
which was just above the limit of detection, and was undetected
at 10 weeks postinfection (P 0.0001) (Fig. 1A). Unmarked B.
melitensis virB2 (BMvirB2) demonstrated similar survival
characteristics to the B. abortus mutant. In this case, BMvirB2
was reduced 2.2 logs compared to 16M (P 0.001). By 6 weeks
postinfection, the mutant strain was undetected from the
mouse spleens (P  0.0001), which held constant at 10 weeks
as well (P  0.002) (Fig. 1B). From these data, we consider
both BAvirB2 and BMvirB2 to be attenuated at a moderate
rate compared to wild-type strains, since they are not cleared
as rapidly as manBA deletion mutants.
The two asp24 deletion mutants were the first set of gene
deletions that portrayed varied survival phenotypes in the
mouse model, depending upon which species of Brucella the
deletion was created. For the B. abortus deletion (BAasp24),
the mutant was highly attenuated (4.6 log reduction) by 6
weeks postinfection (P  0.0001), barely detectable and 5.0
logs reduced at 8 weeks (P  0.0001), and below the limit of
detection at 10 weeks (P  0.0001) (Fig. 1A). In B. melitensis,
however, BMasp24 was not reduced in the spleen at a signif-
icant level until 16 weeks postinfection, where it persisted at
1.2 logs lower than 16M (P  0.04) (Fig. 1B). One difficulty in
assessing the difference between 16M and the knockout arises
from the fact that 16M itself clears at a rapid rate compared to
2308 in mice. As such, differences between 16M and knockouts
are not as pronounced, especially for mutants that exhibit a
delay in attenuation, such as asp24.
Efficacy of B. abortus mutants against 2308 challenge infec-
tion. To evaluate the vaccine potential of the selected un-
marked mutants, the level of protection provided against vir-
ulent challenge infection was assessed. Degree of efficacy was
determined by subtracting the mean CFU/spleen recovered
from mice after vaccination for either 12, 16, or 20 weeks plus
1 week challenge with 2308 (corresponding to 13, 17, and 21
weeks postvaccination, respectively) from the mean CFU/
spleen recovered from age-matched nonvaccinated but chal-
lenged controls. The U value obtained is relative only to the
nonvaccinated controls challenged with the wild type at each
particular time point.
At 13 weeks postvaccination, mice were protected by
BAasp24 at 4.7 U and S19-vaccinated mice at 4.3 U, both
significantly greater than naı¨ve controls (P  0.0001 for both).
Mutants that clear more quickly from the host, BAvirB2 and
BAmanBA, protected mice to a lesser degree at 1.5 and 0.9
U, respectively, but significantly better than naı¨ve mice (P 
0.004 and P  0.001) (Fig. 2A.). At this time point, BAasp24
protected mice significantly better than S19, BAvirB2, and
BAmanBA (P 0.01, P 0.004, and P 0.001, respectively).
There was no significant difference between BAvirB2 and
FIG. 1. Kinetics of clearance of unmarked deletion mutants from
mice. Four to five female BALB/c mice were infected with 2308,
BAasp24, BAvirB2, or BAmanBA (A) or 16 M, BMasp24,
BMvirB2, or BMmanBA (B) at a dose of 1  106 CFU/mouse. Mice
were sacrificed at various time points, and remaining Brucella organ-
isms persisting in the spleens were enumerated and plotted as the
mean CFU/spleen  the standard error. Statistical significance is
based upon an ANOVA comparing the deletion mutant to the wild-
type strain and is listed in the text. The solid line at 0.69 logs represents
the lower limit of detection, which is 5 CFU.
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BAmanBA vaccinates (P  0.22), and both strains protected
mice significantly less than S19 (P  0.004 and P  0.0002,
respectively).
At 17 weeks postvaccination, recovery of the challenge or-
ganism 2308 from a single mouse vaccinated with BAasp24
was just above the limit of detection. The challenge organism
was not recovered from the three remaining mice, which ap-
peared to exhibit sterile immunity. Overall protection for this
group was 4.7 U relative to naı¨ve controls (P  0.0001). S19
protected mice to a similarly high degree at this time point as
well, at 4.4 U (P  0.0001). Mice exhibited 0.9 U protection
when vaccinated with BAvirB2 (P  0.002) or BAmanBA
(P  0.03), suggesting that persistent yet attenuated mutant
strains provide better protection than rapidly cleared mutants
(Fig. 2B). At this time point, the protection provided by
BAasp24 against infection was superior to BAvirB2 and
BAmanBA (P 0.0001 and P 0.0004, respectively), though
there was no significant difference compared to S19 at this time
point (P  0.22). There was no significant difference between
BAvirB2 and BAmanBA groups (P  0.84), and both dele-
tion mutants protected mice significantly less than S19 (P 
0.0001 and P  0.0003, respectively).
At 21 weeks postvaccination, BAasp24 again provided su-
perior protection at 4.5 U (P  0.0001), followed by S19 at
4.3 U (P  0.0001), BAvirB2 at 1.8 U (P  0.001), and
BAmanBA at 0.07 U (P  0.86) relative to naı¨ve controls
(Fig. 2C). Similar to earlier time points, BAasp24 provided
significantly higher levels of protection than BAvirB2 and
BAmanBA (P  0.0001 for both strains) but no significant
difference relative to S19 (P  0.59). Vaccination with
BAvirB2 elicited significantly better protection in mice than
BAmanBA at this time point (P  0.002), although neither
protected as well as S19 (P  0.0004 and P  0.0001, respec-
tively).
Efficacy of B. melitensis mutants against 16M challenge in-
fection. At 13 weeks postvaccination, BMasp24-vaccinated
FIG. 2. Homologous efficacy of B. abortus and B. melitensis vaccine strains. Groups of three to seven female BALB/c mice were vaccinated with
1  106 CFU unmarked B. abortus vaccine strain, S19, or PBS. Groups were allowed to rest for either 12 weeks (A and D), 16 weeks (B and E),
or 20 weeks (C and F) postvaccination. At these time points, mice were subsequently challenged with 1  104 CFU 2308 (A to C) or 16M (D to
F) and allowed to rest 1 week. After 1 week, mice were euthanized via CO2 asphyxiation and spleens were collected. Data are reported as the log10
recovery of Brucella from spleens, with individual mice in each treatment group represented. The solid line at 0.69 logs represents the lower limit
of detection, which is5 CFU. , P 0.05 compared to naı¨ve animals by ANOVA; #, P 0.05 compared to accepted vaccine strain (S19 or Rev 1)
by ANOVA.
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mice exhibited the highest level of protection against virulent
B. melitensis challenge relative to naı¨ve controls, at 3.7 U (P 
0.0001). Rev 1-vaccinated mice were protected at 2.4 U (P 
0.002), BMvirB2-vaccinated mice were protected at 1.9 U,
and BMmanBA-vaccinated mice were protected at 1.5 U
(P  0.04 for both strains) compared to naı¨ve controls (Fig.
2D). At this time point, BMasp24 protected mice significantly
better than Rev 1, BMvirB2, and BMmanBA (P 0.02, P
0.003, and P  0.02, respectively). There was no significant
difference between BMvirB2 or BMmanBA vaccinates (P 
0.67), and there was no significant difference in protection for
these strains compared to Rev 1 (P  0.16 and P  0.45,
respectively).
At 17 weeks postvaccination, BMasp24-vaccinated mice
exhibited the highest level of protection at 5.2 U (P  0.0001),
Rev 1 at 3.7 U (P  0.0001), BMvirB2 at 3.4 U (P  0.0001),
and BMmanBA at 3.4 U (P  0.0002) against virulent B.
melitensis compared to naı¨ve controls (Fig. 2E). At this time
point, BMasp24 protected mice significantly greater than
Rev 1 and BMvirB2 (P  0.006 and P  0.003, respectively),
although there was no significant difference between BMasp24
and BMmanBA due to variation between mice (P  0.07).
There was no significant difference in protection between
BMvirB2 or BMmanBA vaccinates (P  0.92), and there
was no difference for either of these strains compared to Rev
1(P  0.35 and P  0.72, respectively).
At 21 weeks postvaccination, BMasp24 provided the high-
est level of protection relative to naı¨ve mice at 4.7 U (P 
0.0001), followed by Rev 1 at 4.4 U (P 0.0002) (Fig. 2F). The
BMasp24 mutant also protected mice significantly better than
mice vaccinated with BMvirB2 (P 0.003). The BMmanBA
mutant protected mice at 4.1 U and BMvirB2 protected at 2.8
U (P  0.0001 and P  0.0001). The protection provided by
BMasp24 vaccination was equivalent to Rev 1 (P  0.31) but
was statistically indistinguishable from BMmanBA (P 0.07)
due to variations between mice. There was no significant dif-
ference in protection between BMvirB2 and BMmanBA
(P  0.14) or between Rev 1 and BMmanBA (P  0.42),
although Rev 1 vaccination elicited better protection than
BMvirB2 (P  0.04).
Efficacy of unmarked mutants against heterologous Brucella
species. Mice were challenged with a heterologous wild-type
strain to determine if the vaccine would be protective against
another species of Brucella. When challenged with 2308, the
BMasp24 mutant provided the greatest degree of protection
compared to naı¨ve control groups, at 4.2 U (P  0.0001) (Fig.
3A). BMvirB2 provided 3.3 U (P 0.0001), and BMmanBA
provided the least protection at 1.6 U (P  0.02). These data
indicate that, similar to the homologous efficacy data, an
attenuated mutant that persists for a longer period in the
host protects better than mutants that clear rapidly. Mice
that were vaccinated with BMasp24 were protected better
than BMvirB2, though this difference was not significant (P
0.12). Both BMasp24 and BMvirB2 strains elicited signifi-
cantly better protection than BMmanBA (P  0.003 and P 
0.045, respectively).
Vaccination with BAasp24 provided the highest level of
protection against challenge with 16M at 5.1 U relative to naı¨ve
mice (P  0.0001) (Fig. 3B). Mice vaccinated with the
BAvirB2 mutant were significantly protected at 2.1 U (P 
0.0001), and mice vaccinated with BAmanBA were protected
at 1.4 U (P  0.002) relative to naı¨ve mice. BAasp24-vacci-
nated mice were protected better relative to mice vaccinated
with either BAvirB2 (P  0.0002) or BAmanBA (P 
0.002). Although BAvirB2 elicited better protection than
BAmanBA, the difference was not significant between these
two groups (P  0.95).
Production of cytokines from splenocytes of vaccinated mice.
Mouse cytokines were evaluated at 21 weeks in an attempt to
identify correlates of protective immunity associated with the
different vaccine strains. Splenocytes were isolated from mice
and stimulated as described above. Splenocytes from mice
vaccinated with BMasp24 produced the highest amount of
IFN- after stimulation with heat-killed B. melitensis (P 
FIG. 3. Heterologous efficacy of B. abortus and B. melitensis vaccine
strains. Groups of 5 to 10 mice were vaccinated with 1  106 CFU of
unmarked B. melitensis vaccine strain or PBS (A) or 1  106 CFU of
unmarked B. abortus vaccine strains or the PBS control (B). Groups
were allowed to rest for 16 weeks postvaccination, at which time they
were subsequently challenged with 1  104 CFU 2308 (A) or 16M
(B) and allowed to rest for 1 week. After 1 week, mice were euthanized
via CO2 asphyxiation and spleens were collected. Data are reported as
the log10 recovery of Brucella from spleens, with individual mice in
each treatment group represented. The solid line at 0.69 logs repre-
sents the lower limit of detection, which is 5 CFU. , P  0.05
compared to naı¨ve animals by ANOVA.
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0.0001) compared to naı¨ve mice stimulated with the same
antigen (Fig. 4A). Splenocytes from the BMvirB2 vaccination
group also produced a significant amount of IFN- compared
to naı¨ve mice (P  0.02). There was no significant difference
in IFN- production between BMasp24 and BMvirB2
vaccine groups (P  0.12). Splenocytes from mice vacci-
nated with BMmanBA did not produce significant amounts
of IFN- relative to naı¨ve mice (data not shown).
Splenocytes from BAasp24-vaccinated mice produced a
significant amount of IFN- compared to naı¨ve mice when
stimulated in the presence of heat-killed B. abortus (P 0.002)
(Fig. 4B). Production of this cytokine was also greater, though
not significantly, than in BAvirB2 vaccinates (P  0.37). Lev-
els of IFN- from the BAvirB2 splenocytes, though elevated,
were not significant compared to naı¨ve mice (P  0.14).
Relative to naı¨ve controls, IL-10 production from spleno-
cytes of BMasp24 and BMvirB2 vaccinates was significantly
increased (P  0.02 and P  0.03, respectively), and these
levels were not significantly different from one another (P 
0.09) (Fig. 5A). Levels of IL-10 from the BMmanBA group
were not significantly different from naı¨ve mice (data not
shown).
IL-10 production was significantly increased compared to
naı¨ve controls for BAasp24-vaccinated mice only (P  0.05)
(Fig. 5B). There was no significant increase in levels between
any of the other vaccine groups stimulated with heat-killed
Brucella.
DISCUSSION
Since it is not desirable to release an antibiotic resistance
cassette into the field, particularly a transposon, removal of
this resistance while retaining attenuation of the mutant is
ideal. By utilizing homologous recombination between the bac-
terial chromosome and a plasmid carrying cloned chromo-
somal sequences and a selectable marker, unmarked, in-frame
deletions can be created via allelic exchange. Mutants gener-
ated in this fashion were used in the mouse model to demon-
strate a correlation between persistence of the vaccine candi-
date efficacy.
Genes of interest were chosen based upon differences in
survival characteristics of the resulting mutants. Brucella abor-
tus mutants deficient in O-antigen exhibit reduced virulence in
the host and thus have been considered safe candidate live
vaccines (1, 26, 27, 35, 44, 48). Rough mutants are taken up in
greater numbers than smooth strains by macrophages and hu-
man monocytes, exhibit altered trafficking and host defense
responses, and may cause necrotic cell death of the macro-
phages (27, 28, 42, 44). Due to their defect in O-antigen ex-
pression, rough mutants do not interfere with current diagnos-
tic tests but have often proved mildly successful for protection
of target livestock and wildlife species (1, 10, 12, 14, 26, 35, 48).
A virB deletion was chosen because of its inability to persist
within macrophages due to altered trafficking, despite the pres-
ence of O-antigen (7, 9, 13). The contribution of Asp24 to
FIG. 4. IFN- production from mouse splenocytes. Mice were vac-
cinated with 1  106 CFU of B. melitensis deletion mutants (A) or B.
abortus deletion mutants (B) for 21 weeks, with naı¨ve mice kept as
controls. Mice were then euthanized and splenocytes were isolated to
measure in vitro IFN- responses. Splenocytes were stimulated with
either ConA, 1 108 CFU heat-killed 16M (A) or 2308 (B) organisms,
or unstimulated for a baseline cytokine concentration. IFN- produc-
tion (in pg/ml) was detected after 3 days of growth in the presence of
the stimulant and assayed as described in the text, via ELISA.
FIG. 5. IL-10 production from mouse splenocytes. Mice were vac-
cinated with 1  106 CFU of B. melitensis deletion mutants (A) or B.
abortus deletion mutants (B) for 21 weeks, with naı¨ve mice kept as
controls. Mice were then euthanized, and splenocytes were isolated to
measure in vitro IL-10 responses. Splenocytes were stimulated with
either ConA, 1  108 CFU heat-killed 16M (A) or 2308 (B), or
unstimulated for a baseline cytokine concentration. IL-10 production
(in pg/ml) was detected after 3 days of growth in the presence of the
stimulant and assayed as described in the text, via ELISA.
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intracellular survival is unknown, but the upregulated expres-
sion of this gene in macrophages and in response to low pH has
suggested a role in the establishment of an intracellular niche
leading to chronic infection (33). Since deletions in asp24 pos-
sess both intact O-antigen and the type IV secretion system, it
is an ideal candidate to evaluate the importance of both viru-
lence criteria in vaccine efficacy.
The safety of selected vaccine candidates was evaluated
based on clearance of unmarked deletion mutants using the
mouse model. These experiments mimic utilization of the mu-
tant as a vaccine in the field and may be used to estimate the
duration of persistence of the vaccine strain under field con-
ditions. Evaluation of colonization noncompetitively is impor-
tant, since the presence of the wild-type organism can influ-
ence clearance of attenuated mutants from the host and may
suggest enhanced rates of clearance (unpublished results). In
these experiments, we constructed deletion mutants exhibiting
a range of survival characteristics in the mouse model. The
rough mutants, BAmanBA and BMmanBA, were signifi-
cantly reduced in number by 1 week postvaccination but re-
quired 5 weeks postvaccination to be cleared completely. The
virB2 mutants, BAvirB2 and BMvirB2, cleared more grad-
ually than the manBA deletions, suggesting that their defect
affects survival at a later stage of infection. Lastly, BAasp24
and BMasp24 cleared from mice at a much slower rate, with
BAasp24 significantly reduced between 8 and 10 weeks
postinfection and BMasp24 significantly reduced after 16
weeks, suggesting that Asp24 may only be required for persis-
tence of the organism. The differences in survival exhibited by
these mutants provided an opportunity to evaluate the rela-
tionship between protection and persistence of the vaccine
strain.
Protection against homologous challenge (i.e., identical vac-
cine and challenge species) was most successful with the per-
sistent BAasp24 and BMasp24 mutants. These mutants pro-
tected mice against infection at or near sterile levels at all time
points examined. We consider these mutants to be the best
candidates for novel attenuated vaccine strains, since they pro-
tect mice against infection better than current vaccine strains.
In contrast, the rapid clearance of BAvirB2, BMvirB2,
BAmanBA, and BMmanBA may enhance their safety as
vaccine strains but provides significantly reduced levels of pro-
tection compared to asp24 mutants or currently available
vaccine strains. Due to their enhanced safety, however, their
use may be supported if delivered using controlled release,
where the duration and presentation to the host can be ex-
tended to improve efficacy.
In protection studies against heterologous challenge, both
BAasp24 and BMasp24 again protected mice significantly
against challenge, with very few challenge organisms isolated.
These results suggest that survival beyond 8 to 10 weeks does
not enhance protection, and since prolonged survival may have
side effects, the use of BAasp24 as a vaccine strain against
other species of Brucella may be recommended. BAasp24
may be a protective vaccine strain in the event of a bioterrorist
attack or from natural exposure to nonvaccinated, infected
animals, providing cross-species protection.
The degree of protection provided by different vaccine can-
didates was compared with the cytokine profiles elicited from
splenocytes in order to identify any correlates of protective
immunity that may be used to predict potency or efficacy. The
experiments described were designed to evaluate long-term
immune response, mimicking field conditions, in which vacci-
nation is expected to protect against challenge exposure occur-
ring at undefined later dates.
IFN-, a Th1 cytokine involved in pathogen clearance from
activated macrophages, has been well defined as a critical fac-
tor in the control of Brucella abortus infections in mice via
enhanced activation of macrophages and intracellular killing
(3, 21, 40). Infection in mice is more severe when the animals
are treated with antibody to IFN-, and brucellosis becomes a
fatal infection in IFN- knockout mice, confirming the critical
role for IFN- in the early stages of infection (3, 36, 37, 40).
Vaccine candidates asp24 and virB2 produced significant
levels of IFN- in response to stimulation with heat-killed
Brucella relative to naı¨ve mice. However, significant differences
in efficacy determined by reduced recovery of the challenge
strain were not matched by significant differences in IFN-
production. As such, there did not seem to be an absolute
correlation of protection with IFN- in this study, since mice
vaccinated with asp24 mutants demonstrated significantly
higher protection than mice vaccinated with virB2 mutants at
all time points tested. Although increased levels of this cyto-
kine may reflect an improved memory response with subse-
quent protection against challenge, it appears that IFN-, al-
though necessary, is not sufficient to provide protection against
infection. IFN- was not induced significantly in mice vacci-
nated with a rough mutant, manBA. In other studies evalu-
ating cytokine responses from splenocytes from mice vacci-
nated with rough mutants, a similar result was published (1).
IL-10 is generally considered an antiinflammatory molecule,
thought to reduce negative effects caused by proinflammatory
cytokines such as IFN- (47). Evidence suggests that inhibition
of IL-10 activity results in improved clearance of B. abortus
from the spleens of infected mice (16, 20). Since BALB/c mice
are known to mount a very strong inflammatory response early
in Brucella infection, Th2 cytokines such as IL-10 may be nec-
essary to prevent overwhelming the host and to limit the influx
of phagocytic cells and potential spread of the disease (3, 19,
41). Recently, it has been shown that IL-10 develops proin-
flammatory qualities during active inflammatory responses
(47). The fact that IL-10 was generally increased in these
experiments compared to naı¨ve controls for BMasp24,
BAasp24, and BMvirB2 may be related to the observed
levels of protection, suggesting a proinflammatory role in the
mouse model.
In this study, mice were vaccinated for 20 weeks, and since
previous research has never considered such late time points in
the mouse, direct comparisons cannot be made to published
work. Splenocytes may not be the ideal tissue to evaluate
long-term cytokine responses in animals vaccinated for ex-
tended periods, and another tissue such as lymph nodes may
need to be considered to identify correlates of immunity asso-
ciated with protection.
Overall, the mouse is a sensitive and popular model for
evaluating brucellosis. This model has been invaluable for
characterization of genetic components necessary for virulence
and is an affordable and consistent method for evaluation of
potential vaccine candidates (15, 18, 25). Mutants considered
safe and protective in the mouse model are often used as
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candidates for vaccines in target animal species. The mouse
model cannot be used, however, to gauge the effect of persis-
tence on the colonization of reproductive tissues, thus, the
need for other animal models after the initial murine screen.
Since the mouse is not an exact model of disease in target
livestock and wildlife species, vaccine candidates from the
mouse will need to be reevaluated in a suitable animal model.
The asp24 deletion mutants were the most protective in the
mouse screen against both homologous and heterologous chal-
lenge infections, and perhaps their protective ability in target
species may be superior to the other candidates in that model
as well.
ACKNOWLEDGMENTS
Melissa Kahl-McDonagh was supported by USDA Food and Agri-
cultural Sciences National Needs Graduate Fellowship Grant 98-
38420-5806 (CSREES) and an NIH Training Grant Predoctoral Fel-
lowship Award. Research was funded by USDA/CSREES-NRICGP
99-35204-7550 and NIH 1RO1 AI48496-01.
pEX18Ap was kindly given to the Ficht lab by Herbert Schweizer.
REFERENCES
1. Adone, R., F. Ciuchini, C. Marianelli, M. Tarantino, C. Pistoia, G. Marcon,
P. Petrucci, M. Francia, G. Riccardi, and P. Pasquali. 2005. Protective
properties of rifampin-resistant rough mutants of Brucella melitensis. Infect.
Immun. 73:4198–4204.
2. Allen, C. A., L. G. Adams, and T. A. Ficht. 1998. Transposon-derived Brucella
abortus rough mutants are attenuated and exhibit reduced intracellular sur-
vival. Infect. Immun. 66:1008–1016.
3. Baldwin, C. L., and M. Parent. 2002. Fundamentals of host immune re-
sponse against Brucella abortus: what the mouse model has revealed about
control of infection. Vet. Microbiol. 90:367–382.
4. Bardenstein, S., M. Mandelboim, T. A. Ficht, M. Baum, and M. Banai. 2002.
Identification of the Brucella melitensis vaccine strain Rev 1 in animals and
humans in Israel by PCR analysis of the PstI site polymorphism of its omp2
gene. J. Clin. Microbiol. 40:1475–1480.
5. Boschiroli, M. L., S. Ouahrani-Bettache, V. Foulongne, S. Michaux-
Charachon, G. Bourg, A. Allardet-Servent, C. Cazevieille, J. P. Lavigne,
J. P. Liautard, M. Ramuz, and D. O’Callaghan. 2002. Type IV secretion
and Brucella virulence. Vet. Microbiol. 90:341–348.
6. Boschiroli, M. L., S. Ouahrani-Bettache, V. Foulongne, S. Michaux-
Charachon, G. Bourg, A. Allardet-Servent, C. Cazevieille, J. P. Liautard,
M. Ramuz, and D. O’Callaghan. 2002. The Brucella suis virB operon is
induced intracellularly in macrophages. Proc. Natl. Acad. Sci. USA 99:
1544–1549.
7. Celli, J., C. de Chastellier, D. M. Franchini, J. Pizarro-Cerda, E. Moreno,
and J. P. Gorvel. 2003. Brucella evades macrophage killing via VirB-depen-
dent sustained interactions with the endoplasmic reticulum. J. Exp. Med.
198:545–556.
8. Celli, J., and J. P. Gorvel. 2004. Organelle robbery: Brucella interactions
with the endoplasmic reticulum. Curr. Opin. Microbiol. 7:93–97.
9. Comerci, D. J., M. J. Martinez-Lorenzo, R. Sieira, J. P. Gorvel, and R. A.
Ugalde. 2001. Essential role of the VirB machinery in the maturation of the
Brucella abortus-containing vacuole. Cell. Microbiol. 3:159–168.
10. Cook, W. E., E. S. Williams, E. T. Thorne, T. J. Kreeger, G. Stout, K.
Bardsley, H. Edwards, G. Schurig, L. A. Colby, F. Enright, and P. H. Elzer.
2002. Brucella abortus strain RB51 vaccination in elk. I. Efficacy of reduced
dosage. J. Wildl. Dis. 38:18–26.
11. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromo-
somal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad.
Sci. USA 97:6640–6645.
12. Davis, D. S., and P. H. Elzer. 2002. Brucella vaccines in wildlife. Vet.
Microbiol. 90:533–544.
13. den Hartigh, A. B., Y. H. Sun, D. Sondervan, N. Heuvelmans, M. O.
Reinders, T. A. Ficht, and R. M. Tsolis. 2004. Differential requirements
for VirB1 and VirB2 during Brucella abortus infection. Infect. Immun.
72:5143–5149.
14. Elzer, P. H., J. Smith, T. Roffe, T. Kreeger, J. Edwards, and D. Davis. 2002.
Evaluation of Brucella abortus strain RB51 and strain 19 in pronghorn
antelope. Ann. N. Y. Acad. Sci. 969:102–105.
15. Endley, S., D. McMurray, and T. A. Ficht. 2001. Interruption of the cydB
locus in Brucella abortus attenuates intracellular survival and virulence in the
mouse model of infection. J. Bacteriol. 183:2454–2462.
16. Fernandes, D. M., and C. L. Baldwin. 1995. Interleukin-10 downregulates
protective immunity to Brucella abortus. Infect. Immun. 63:1130–1133.
17. Ficht, T. A. 2002. Discovery of Brucella virulence mechanisms using muta-
tional analysis. Vet. Microbiol. 90:311–315.
18. Ficht, T. A. 2003. Intracellular survival of Brucella: defining the link with
persistence. Vet. Microbiol. 92:213–223.
19. Forestier, C., F. Deleuil, N. Lapaque, E. Moreno, and J. P. Gorvel. 2000.
Brucella abortus lipopolysaccharide in murine peritoneal macrophages acts
as a down-regulator of T cell activation. J. Immunol. 165:5202–5210.
20. Giambartolomei, G. H., M. V. Delpino, M. E. Cahanovich, J. C. Wallach,
P. C. Baldi, C. A. Velikovsky, and C. A. Fossati. 2002. Diminished production
of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella
cytoplasmic proteins in chronic human brucellosis. J. Infect. Dis. 186:252–
259.
21. Golding, B., D. E. Scott, O. Scharf, L. Y. Huang, M. Zaitseva, C. Lapham, N.
Eller, and H. Golding. 2001. Immunity and protection against Brucella
abortus. Microbes Infect. 3:43–48.
22. Hamdy, M. E., S. M. El-Gibaly, and A. M. Montasser. 2002. Comparison
between immune responses and resistance induced in BALB/c mice vacci-
nated with RB51 and Rev 1 vaccines and challenged with Brucella melitensis
bv. 3. Vet. Microbiol. 88:85–94.
23. Hoang, T. T., R. R. Karkhoff-Schweizer, A. J. Kutchma, and H. P. Schweizer.
1998. A broad-host-range Flp-FRT recombination system for site-specific
excision of chromosomally-located DNA sequences: application for isolation
of unmarked Pseudomonas aeruginosa mutants. Gene 212:77–86.
24. Hong, P. 2005. Ph.D. dissertation. Texas A&M University, College Station.
25. Hong, P. C., R. M. Tsolis, and T. A. Ficht. 2000. Identification of genes
required for chronic persistence of Brucella abortus in mice. Infect. Immun.
68:4102–4107.
26. Jimenez de Bagues, M. P., P. H. Elzer, S. M. Jones, J. M. Blasco, F. M.
Enright, G. G. Schurig, and A. J. Winter. 1994. Vaccination with Brucella
abortus rough mutant RB51 protects BALB/c mice against virulent strains of
Brucella abortus, Brucella melitensis, and Brucella ovis. Infect. Immun. 62:
4990–4996.
27. Jimenez de Bagues, M. P., A. Gross, A. Terraza, and J. Dornand. 2005.
Regulation of the mitogen-activated protein kinases by Brucella spp. express-
ing a smooth and rough phenotype: relationship to pathogen invasiveness.
Infect. Immun. 73:3178–3183.
28. Jimenez de Bagues, M. P., A. Terraza, A. Gross, and J. Dornand. 2004.
Different responses of macrophages to smooth and rough Brucella spp.:
relationship to virulence. Infect. Immun. 72:2429–2433.
29. Ko, J., and G. A. Splitter. 2003. Molecular host-pathogen interaction in
brucellosis: current understanding and future approaches to vaccine devel-
opment for mice and humans. Clin. Microbiol. Rev. 16:65–78.
30. Kohler, S., S. Michaux-Charachon, F. Porte, M. Ramuz, and J. P. Liautard.
2003. What is the nature of the replicative niche of a stealthy bug named
Brucella? Trends Microbiol. 11:215–219.
31. Lai, F., G. G. Schurig, and S. M. Boyle. 1990. Electroporation of a suicide
plasmid bearing a transposon into Brucella abortus. Microb. Pathog. 9:363–
368.
32. Lestrate, P., R. M. Delrue, I. Danese, C. Didembourg, B. Taminiau, P.
Mertens, X. De Bolle, A. Tibor, C. M. Tang, and J. J. Letesson. 2000.
Identification and characterization of in vivo attenuated mutants of Brucella
melitensis. Mol. Microbiol. 38:543–551.
33. Lin, J., and T. A. Ficht. 1995. Protein synthesis in Brucella abortus induced
during macrophage infection. Infect. Immun. 63:1409–1414.
34. Monreal, D., M. J. Grillo, D. Gonzalez, C. M. Marin, M. J. De Miguel, I.
Lopez-Goni, J. M. Blasco, A. Cloeckaert, and I. Moriyon. 2003. Character-
ization of Brucella abortus O-polysaccharide and core lipopolysaccharide
mutants and demonstration that a complete core is required for rough
vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse
model. Infect. Immun. 71:3261–3271.
35. Moriyon, I., M. J. Grillo, D. Monreal, D. Gonzalez, C. Marin, I. Lopez-Goni,
R. C. Mainar-Jaime, E. Moreno, and J. M. Blasco. 2004. Rough vaccines in
animal brucellosis: structural and genetic basis and present status. Vet. Res.
35:1–38.
36. Murphy, E. A., M. Parent, J. Sathiyaseelan, X. Jiang, and C. L. Baldwin.
2001. Immune control of Brucella abortus 2308 infections in BALB/c mice.
FEMS Immunol. Med. Microbiol. 32:85–88.
37. Murphy, E. A., J. Sathiyaseelan, M. A. Parent, B. Zou, and C. L. Baldwin.
2001. Interferon-gamma is crucial for surviving a Brucella abortus infection
in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103:
511–518.
38. Murphy, K. C., K. G. Campellone, and A. R. Poteete. 2000. PCR-mediated
gene replacement in Escherichia coli. Gene 246:321–330.
39. Oliveira, S. C., N. Soeurt, and G. Splitter. 2002. Molecular and cellular
interactions between Brucella abortus antigens and host immune responses.
Vet. Microbiol. 90:417–424.
40. Paranavitana, C., E. Zelazowska, M. Izadjoo, and D. Hoover. 2005. Inter-
feron-gamma associated cytokines and chemokines produced by spleen cells
from Brucella-immune mice. Cytokine 30:86–92.
41. Pasquali, P., R. Adone, L. C. Gasbarre, C. Pistoia, and F. Ciuchini. 2001.
Mouse cytokine profiles associated with Brucella abortus RB51 vaccination
or B. abortus 2308 infection. Infect. Immun. 69:6541–6544.
4056 KAHL-MCDONAGH AND FICHT INFECT. IMMUN.
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
42. Pei, J., and T. A. Ficht. 2004. Brucella abortus rough mutants are cytopathic
for macrophages in culture. Infect. Immun. 72:440–450.
43. Porte, F., A. Naroeni, S. Ouahrani-Bettache, and J. P. Liautard. 2003. Role
of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and
in inhibition of phagosome-lysosome fusion in murine macrophages. Infect.
Immun. 71:1481–1490.
44. Rittig, M. G., A. Kaufmann, A. Robins, B. Shaw, H. Sprenger, D. Gemsa, V.
Foulongne, B. Rouot, and J. Dornand. 2003. Smooth and rough lipopolysac-
charide phenotypes of Brucella induce different intracellular trafficking and
cytokine/chemokine release in human monocytes. J. Leukoc. Biol. 74:1045–
1055.
45. Schurig, G. G., R. M. Roop II, T. Bagchi, S. Boyle, D. Buhrman, and N.
Sriranganathan. 1991. Biological properties of RB51; a stable rough strain
of Brucella abortus. Vet. Microbiol. 28:171–188.
46. Schurig, G. G., N. Sriranganathan, and M. J. Corbel. 2002. Brucellosis
vaccines: past, present and future. Vet. Microbiol. 90:479–496.
47. Sharif, M. N., I. Tassiulas, Y. Hu, I. Mecklenbrauker, A. Tarakhovsky, and
L. B. Ivashkiv. 2004. IFN-alpha priming results in a gain of proinflammatory
function by IL-10: implications for systemic lupus erythematosus pathogen-
esis. J. Immunol. 172:6476–6481.
48. Ugalde, J. E., D. J. Comerci, M. S. Leguizamon, and R. A. Ugalde. 2003.
Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new
live rough-phenotype vaccine. Infect. Immun. 71:6264–6269.
49. Ugalde, J. E., C. Czibener, M. F. Feldman, and R. A. Ugalde. 2000. Identi-
fication and characterization of the Brucella abortus phosphoglucomutase
gene: role of lipopolysaccharide in virulence and intracellular multiplication.
Infect. Immun. 68:5716–5723.
Editor: V. J. DiRita
VOL. 74, 2006 UNMARKED MUTANT EFFICACY AGAINST BRUCELLA INFECTION 4057
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
